|
MARLBOROUGH, Mass., July 8, 2024 -- Boston Scientific Corporation (NYSE: BSX) today announced the company’s clinical data will be featured at the sixth annual American Society of Pain & Neuroscience (ASPN) conference, which will be held in Miami Beach, Florida, on July 11-14, 2024. A total of 15 abstracts and posters will be presented, including a study of five-year pooled data for the Intracept™ Procedure System that measures outcomes across three clinical trials. The Intracept procedure system includes the only U.S. Food and Drug Administration cleared devices for the treatment of vertebrogenic low back pain, a distinct type of pain caused by damage to vertebral endplates, which interface between the disc and the vertebral body. The pooled data are based on a five-year follow-up study of 249 patients with vertebrogenic pain and treated with the Intracept procedure system. Patient-reported Oswestry Disability Index (ODI) and numeric pain scores were compared to baseline. Secondary outcomes measured included numeric pain score quartiles, responder rates, patient satisfaction and healthcare utilization. Of the 30 million people in the U.S. with chronic low back pain, one in six are likely to have vertebrogenic pain[1] Patients typically have pain in the middle of their low back, which worsens when they bend over, sit for long periods of time, or when they are active. A physician can confirm a patient’s pain is vertebrogenic by observing modic changes, a biomarker seen on standard MRI that indicates inflammation at the vertebral endplate. "Boston Scientific provides innovative solutions that help patients with chronic pain and neurological conditions get back to their daily lives,” said Ray Baker, M.D., vice president and chief medical officer, Neuromodulation, Boston Scientific. "The data shared at the 2024 ASPN Annual Meeting demonstrate the clinical effectiveness of our entire interventional pain portfolio, including meaningful clinical evidence on lasting relief from vertebrogenic pain.” Additional data to be presented by Boston Scientific include clinical outcomes on FAST™ Therapy (Fast-Acting Sub-Perception Therapy) with spinal cord stimulation (SCS) as well as one-year results from the SOLIS (SCS as an Option for Chronic Low Back and/or Leg Pain Instead of Surgery) randomized control trial. Featured Presentations Poster presentations:
Oral presentations:
For a complete list of Boston Scientific clinical and scientific data presentations at the 2024 ASPN conference, please visit: www.bostonscientific.com/ASPN2024. About the Boston Scientific Chronic Pain Portfolio The Boston Scientific portfolio of advanced chronic pain management solutions is designed to deliver lasting relief to improve the quality of life for the millions of people living with pain worldwide. Supported by robust clinical evidence, the comprehensive suite of transformative therapies includes the WaveWriter Alpha™ Spinal Cord Stimulator System, Intracept™ Procedure, Radiofrequency Ablation, and the Vertiflex™ Procedure† to provide safe and effective therapy options that help physicians address the unique needs of their patients. About Boston Scientific Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, product performance and impact, new and anticipated product approvals and launches and clinical trials. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Factors that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including cost savings and growth initiatives; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release. CONTACTS: Media: Lisa Ferrer Investor Relations: Jon Monson |
|
Intracept Procedure System = Intracept Intraosseous Nerve Ablation System
|
[1] Hoy D, March L, Brooks P, et al. The global burden of low back pain; estimates from the Global Burden of Disease 2010 study. Annals of the Rheumatic Diseases 2014;73:968-974. https://ard.bmj.com/content/73/6/968;The global point prevalence of LBP was 9.4% (95% CI 9.0 to 9.8), (333M U.S. pop * 9.4% = 31M); Lorio et al. International Journal of Spine Surgery December 2022, 16 (6) 1084-1094; DOI: https://doi.org/10.14444/8362;http://www.ijssurgery.com/content/16/6/1084; estimated that 15% of CLBP patients suffer from primary vertebrogenic pain.